MedTrace Logo

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-17

No results posted yet for this study

Summary

A Phase 2 in Adult Subjects with Hereditary Angioedema

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

BW-20805

SC administrations of BW-20805 600 mg on Day1 to Day673

DRUG

BW-20805

SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673

DRUG

BW-20805

SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589

Sponsors & Collaborators

  • Shanghai Argo Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Markus Magerl, Doctor · Charite-Universitaetsmedizin Berlin - Klinik fuer Dermatologie Venerologie und Allergologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2026-06-30
Completion
2028-03-30
FDA Drug
Yes

Countries

  • United States
  • China
  • Germany
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06846398 on ClinicalTrials.gov